Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 10/20 | 0.42 |
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932231 | 0.93 | FYN (0.42) | FYNPIM1IKBKBERN1MKNK1 | |
| SCHEMBL23931845 | 0.85 | FYN (0.42) | FYNPIM1IKBKBERN1MKNK1 | |
| SCHEMBL23932131 | 0.83 | FYN (0.42) | FYNPIM1IKBKBERN1MKNK1 | |
| SCHEMBL23931952 | 0.82 | ERN1 (0.49) | FYNPIM1IKBKBERN1RIPK2 | |
| SCHEMBL23932050 | 0.82 | FYN (0.56) | FYNPIM1IKBKBERN1MKNK1 | |
| SCHEMBL23932104 | 0.80 | ERN1 (0.57) | FYNPIM1ERN1DYRK1ARIPK2 | |
| SCHEMBL23932083 | 0.80 | FYN (0.66) | FYNPIM1MKNK1 | |
| SCHEMBL23932159 | 0.80 | FYN (0.47) | FYNPIM1MKNK1NTRK1NTRK3 | |
| SCHEMBL25726401 | 0.79 | FYN (0.65) | FYNPIM1ERN1DYRK1ARIPK2 | |
| SCHEMBL23932106 | 0.78 | NTRK1 (0.45) | FYNPIM1IKBKBMKNK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | HNRNPR, HNRNPAB, RBM3 | FYN 2657/4885PIM1 1866/4885IKBKB 805/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | FYN 2657/4885PIM1 1866/4885IKBKB 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.